Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK6 | Q00534 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.40 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 3/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590072 | 1.00 | CDK6 (0.42) | CDK6GAAHDAC3HDAC2HPGD | |
| SCHEMBL20246641 | 0.96 | HPGD (0.41) | CDK6GAAHDAC3HDAC2HPGD | |
| SCHEMBL29590152 | 0.84 | HDAC3 (0.50) | CDK6GAAHDAC3HDAC2HPGD | |
| SCHEMBL14783117 | 0.84 | HDAC3 (0.50) | CDK6GAAHDAC3HDAC2HPGD | |
| SCHEMBL20749378 | 0.83 | CDK6 (0.41) | CDK6HDAC3HDAC2HPGDPIK3CD | |
| SCHEMBL29590318 | 0.83 | KDM4E (0.56) | GAA | |
| SCHEMBL14784324 | 0.83 | KDM4E (0.56) | GAA | |
| SCHEMBL20749358 | 0.83 | CDK6 (0.42) | CDK6HDAC3HDAC2HPGDPIK3CD | |
| SCHEMBL15689342 | 0.83 | GBA1 (0.45) | GAAHPGDPIK3CDPIK3CAKCNQ3 | |
| SCHEMBL14783938 | 0.83 | PIK3CA (0.46) | CDK6HDAC3HDAC2HPGDPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116880-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC | 2024-04-11 | — | — | US | disclosed |
| CN-116887833-A | Certain chemical entities, compositions and methods | 润新生物公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4255434-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-115403531-A | Chemical entities, compositions, and methods as kinase inhibitors | 润新生物公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2022-08-11 | — | — | US | disclosed |
| WO-2022119905-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022119905-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC (US) | 2022-06-09 | — | — | WO | disclosed |
| CN-108794411-B | Certain chemical entities, compositions, and methods | 润新生物公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| EP-2755657-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2747767-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013032951-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013032951-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | NEUPHARMA, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116880-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TP53, VHL, RB1 | CDK6 1103/4885GAA 923/4885HDAC3 1512/4885 |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | CDK6 54/4885GAA 2553/4885HDAC3 2571/4885 |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | CDK6 54/4885GAA 2917/4885HDAC3 2771/4885 |
| US-20130053384-A1 | Certain Chemical Entities, Compositions, and Methods | BRAF, PIK3CA, PLK1 | CDK6 110/4885GAA 1540/4885HDAC3 1072/4885 |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | CDK6 54/4885GAA 2917/4885HDAC3 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.